Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

H. Einstein, Mark; Baron, Mira; J. Levin, Myron; Chatterjee, Archana; Fox, Bradley; Scholar, Sofia; B. Rosen, Jeffrey; Chakhtoura, Nahida; Lebacq, Marie; van der Most, Robbert; Moris, Philippe; L. Giannini, Sandra; Schuind, Anne; Datta, Sanjoy; Descamps, Dominique

doi:10.4161/hv.7.12.18282

Public

Comparison of the immunogenicity of the human papillomavirus (HPV)-16/18 vaccine and the HPV-6/11/16/18 vaccine for oncogenic non-vaccine types HPV-31 and HPV-45 in healthy women aged 18–45 years

Published in Human Vaccines • Dec 1, 2011

Authors:

Mark H. Einstein

Mira Baron

Myron J. Levin

Abstract

Protection against oncogenic non-vaccine types (cross-protection) offered by human papillomavirus (HPV) vaccines may provide a significant medical benefit. Available clinical efficacy data suggest the two licensed vaccines (HPV-16/18 vaccine, GlaxoSmithKline Biologicals (GSK), and HPV-6/11/16/18 vac...

Subject

Medicine

Immunogenicity

Virology

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!